Usefulness of Growth Differentiation Factor-15 Levels to Predict Diabetic Cardiomyopathy in Asymptomatic Patients With Type 2 Diabetes Mellitus
Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine that increased in patients with established type 2 diabetes mellitus (DM). Diabetic cardiomyopathy (DC), defined as left ventricular diastolic dysfunction (LVDD) in patients with type 2 DM in the absence of arterial hypertensi...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2014-09, Vol.114 (6), p.890-894 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 894 |
|---|---|
| container_issue | 6 |
| container_start_page | 890 |
| container_title | The American journal of cardiology |
| container_volume | 114 |
| creator | Dominguez-Rodriguez, Alberto, MD, PhD Abreu-Gonzalez, Pedro, PhD Avanzas, Pablo, MD, PhD |
| description | Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine that increased in patients with established type 2 diabetes mellitus (DM). Diabetic cardiomyopathy (DC), defined as left ventricular diastolic dysfunction (LVDD) in patients with type 2 DM in the absence of arterial hypertension, heart disease, or other heart disease, was assessed by GDF-15 levels in type 2 DM patients with and without DC. A total of 213 DM outpatients had blood samples drawn and on the same day (basal) underwent echocardiography and treadmill exercise testing. Plasma GDF-15 concentrations were measured by an enzyme-linked immunosorbent assay (ELISA) at baseline. DC was diagnosed in the presence of LVDD, defined when early mitral valve flow velocity (E) and early diastolic lengthening velocity (E′) ratio was E/E′ ≥15. The prevalence of DC was 21.13%. GDF-15 levels were higher in patients with DC compared with those without DC (5,273 [8,708.4] vs 2,812.66 [7,662.1] pg/ml, respectively, p |
| doi_str_mv | 10.1016/j.amjcard.2014.06.020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1561969806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914914013678</els_id><sourcerecordid>1561969806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c551t-d9beb2106fc660cf700aac305f3464933754105267e38d471600d04795e5412d3</originalsourceid><addsrcrecordid>eNqFUsFu1DAQjRCIbgufALLEhUvCTBw7mwuoWmhBWkQlWnG0vM5E9ZLEW9spylf0l_FqF5B64WLLmjdvnt-bLHuFUCCgfLct9LA12rdFCVgVIAso4Um2wGXd5Nggf5otAKDMG6yak-w0hG16Igr5PDspBdRcyGqRPdwE6qZ-pBCY69ild7_iLftou448jdHqaN3ILrSJzuco2JruqQ8sOnblqbUmJqzeULSGrZIY64bZ7XS8nZkd2XmYh110g96Xr9KZGAP7YdOE63lHrDw2U2Bfqe9tnMKL7Fmn-0Avj_dZdnPx6Xr1OV9_u_yyOl_nRgiMedtsaFMiyM5ICaarAbQ2HETHK1k1nNeiQhClrIkv26pGCdBCVTeCUqFs-Vn29sC78-5uohDVYINJIvRIbgoq-YSNbJYgE_TNI-jWTX5M6hRK5EuUJYeEEgeU8S4ET53aeTtoPysEtU9MbdUxMbVPTIFUKbHU9_rIPm0Gav92_YkoAT4cAMl3urfkVTDJSJPc92Siap3974j3jxhMb0drdP-TZgr_fqNCqUB936_NfmuwAuSyXvLfvW-99A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1613816230</pqid></control><display><type>article</type><title>Usefulness of Growth Differentiation Factor-15 Levels to Predict Diabetic Cardiomyopathy in Asymptomatic Patients With Type 2 Diabetes Mellitus</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><creator>Dominguez-Rodriguez, Alberto, MD, PhD ; Abreu-Gonzalez, Pedro, PhD ; Avanzas, Pablo, MD, PhD</creator><creatorcontrib>Dominguez-Rodriguez, Alberto, MD, PhD ; Abreu-Gonzalez, Pedro, PhD ; Avanzas, Pablo, MD, PhD</creatorcontrib><description>Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine that increased in patients with established type 2 diabetes mellitus (DM). Diabetic cardiomyopathy (DC), defined as left ventricular diastolic dysfunction (LVDD) in patients with type 2 DM in the absence of arterial hypertension, heart disease, or other heart disease, was assessed by GDF-15 levels in type 2 DM patients with and without DC. A total of 213 DM outpatients had blood samples drawn and on the same day (basal) underwent echocardiography and treadmill exercise testing. Plasma GDF-15 concentrations were measured by an enzyme-linked immunosorbent assay (ELISA) at baseline. DC was diagnosed in the presence of LVDD, defined when early mitral valve flow velocity (E) and early diastolic lengthening velocity (E′) ratio was E/E′ ≥15. The prevalence of DC was 21.13%. GDF-15 levels were higher in patients with DC compared with those without DC (5,273 [8,708.4] vs 2,812.66 [7,662.1] pg/ml, respectively, p <0.001). We assessed predictors of DC using multivariate regression analysis. GDF-15 (odds ratio 9.9; 95% confidence interval [3.9 to 24.5], p <0.001) was the unique independent predictor of DC. The results of receiver operating characteristic curve show that the cut-off point of 3,812 pg/ml of GDF-15 was indicative for DC (AUC = 0.83, sensitivity = 82.2% and specificity = 70.2%, p <0.0001). In conclusion, GDF-15 represents a useful and novel tool to screen DC in patients with type 2 DM.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2014.06.020</identifier><identifier>PMID: 25073564</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Biomarkers - blood ; Body mass index ; Cardiomyopathy ; Cardiovascular ; Cardiovascular disease ; Confidence intervals ; Cytokines ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetic Cardiomyopathies - blood ; Diabetic Cardiomyopathies - epidemiology ; Diabetic Cardiomyopathies - etiology ; Echocardiography ; Electrocardiography ; Enzyme-Linked Immunosorbent Assay ; Enzymes ; Exercise Test ; Female ; Fitness equipment ; Flow velocity ; Gender ; Growth Differentiation Factor 15 - blood ; Heart attacks ; Heart failure ; Heart Ventricles - diagnostic imaging ; Heart Ventricles - physiopathology ; Humans ; Hypertension ; Logistics ; Male ; Middle Aged ; Normal distribution ; Oxidative Stress ; Prevalence ; Prognosis ; Regression analysis ; ROC Curve ; Spain - epidemiology ; Statins ; Stroke Volume ; Variables</subject><ispartof>The American journal of cardiology, 2014-09, Vol.114 (6), p.890-894</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 15, 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c551t-d9beb2106fc660cf700aac305f3464933754105267e38d471600d04795e5412d3</citedby><cites>FETCH-LOGICAL-c551t-d9beb2106fc660cf700aac305f3464933754105267e38d471600d04795e5412d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1613816230?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982,64370,64372,64374,72226</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25073564$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dominguez-Rodriguez, Alberto, MD, PhD</creatorcontrib><creatorcontrib>Abreu-Gonzalez, Pedro, PhD</creatorcontrib><creatorcontrib>Avanzas, Pablo, MD, PhD</creatorcontrib><title>Usefulness of Growth Differentiation Factor-15 Levels to Predict Diabetic Cardiomyopathy in Asymptomatic Patients With Type 2 Diabetes Mellitus</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine that increased in patients with established type 2 diabetes mellitus (DM). Diabetic cardiomyopathy (DC), defined as left ventricular diastolic dysfunction (LVDD) in patients with type 2 DM in the absence of arterial hypertension, heart disease, or other heart disease, was assessed by GDF-15 levels in type 2 DM patients with and without DC. A total of 213 DM outpatients had blood samples drawn and on the same day (basal) underwent echocardiography and treadmill exercise testing. Plasma GDF-15 concentrations were measured by an enzyme-linked immunosorbent assay (ELISA) at baseline. DC was diagnosed in the presence of LVDD, defined when early mitral valve flow velocity (E) and early diastolic lengthening velocity (E′) ratio was E/E′ ≥15. The prevalence of DC was 21.13%. GDF-15 levels were higher in patients with DC compared with those without DC (5,273 [8,708.4] vs 2,812.66 [7,662.1] pg/ml, respectively, p <0.001). We assessed predictors of DC using multivariate regression analysis. GDF-15 (odds ratio 9.9; 95% confidence interval [3.9 to 24.5], p <0.001) was the unique independent predictor of DC. The results of receiver operating characteristic curve show that the cut-off point of 3,812 pg/ml of GDF-15 was indicative for DC (AUC = 0.83, sensitivity = 82.2% and specificity = 70.2%, p <0.0001). In conclusion, GDF-15 represents a useful and novel tool to screen DC in patients with type 2 DM.</description><subject>Biomarkers - blood</subject><subject>Body mass index</subject><subject>Cardiomyopathy</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Confidence intervals</subject><subject>Cytokines</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetic Cardiomyopathies - blood</subject><subject>Diabetic Cardiomyopathies - epidemiology</subject><subject>Diabetic Cardiomyopathies - etiology</subject><subject>Echocardiography</subject><subject>Electrocardiography</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Enzymes</subject><subject>Exercise Test</subject><subject>Female</subject><subject>Fitness equipment</subject><subject>Flow velocity</subject><subject>Gender</subject><subject>Growth Differentiation Factor 15 - blood</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Heart Ventricles - diagnostic imaging</subject><subject>Heart Ventricles - physiopathology</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Logistics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Normal distribution</subject><subject>Oxidative Stress</subject><subject>Prevalence</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>ROC Curve</subject><subject>Spain - epidemiology</subject><subject>Statins</subject><subject>Stroke Volume</subject><subject>Variables</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFUsFu1DAQjRCIbgufALLEhUvCTBw7mwuoWmhBWkQlWnG0vM5E9ZLEW9spylf0l_FqF5B64WLLmjdvnt-bLHuFUCCgfLct9LA12rdFCVgVIAso4Um2wGXd5Nggf5otAKDMG6yak-w0hG16Igr5PDspBdRcyGqRPdwE6qZ-pBCY69ild7_iLftou448jdHqaN3ILrSJzuco2JruqQ8sOnblqbUmJqzeULSGrZIY64bZ7XS8nZkd2XmYh110g96Xr9KZGAP7YdOE63lHrDw2U2Bfqe9tnMKL7Fmn-0Avj_dZdnPx6Xr1OV9_u_yyOl_nRgiMedtsaFMiyM5ICaarAbQ2HETHK1k1nNeiQhClrIkv26pGCdBCVTeCUqFs-Vn29sC78-5uohDVYINJIvRIbgoq-YSNbJYgE_TNI-jWTX5M6hRK5EuUJYeEEgeU8S4ET53aeTtoPysEtU9MbdUxMbVPTIFUKbHU9_rIPm0Gav92_YkoAT4cAMl3urfkVTDJSJPc92Siap3974j3jxhMb0drdP-TZgr_fqNCqUB936_NfmuwAuSyXvLfvW-99A</recordid><startdate>20140915</startdate><enddate>20140915</enddate><creator>Dominguez-Rodriguez, Alberto, MD, PhD</creator><creator>Abreu-Gonzalez, Pedro, PhD</creator><creator>Avanzas, Pablo, MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20140915</creationdate><title>Usefulness of Growth Differentiation Factor-15 Levels to Predict Diabetic Cardiomyopathy in Asymptomatic Patients With Type 2 Diabetes Mellitus</title><author>Dominguez-Rodriguez, Alberto, MD, PhD ; Abreu-Gonzalez, Pedro, PhD ; Avanzas, Pablo, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c551t-d9beb2106fc660cf700aac305f3464933754105267e38d471600d04795e5412d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Biomarkers - blood</topic><topic>Body mass index</topic><topic>Cardiomyopathy</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Confidence intervals</topic><topic>Cytokines</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetic Cardiomyopathies - blood</topic><topic>Diabetic Cardiomyopathies - epidemiology</topic><topic>Diabetic Cardiomyopathies - etiology</topic><topic>Echocardiography</topic><topic>Electrocardiography</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Enzymes</topic><topic>Exercise Test</topic><topic>Female</topic><topic>Fitness equipment</topic><topic>Flow velocity</topic><topic>Gender</topic><topic>Growth Differentiation Factor 15 - blood</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Heart Ventricles - diagnostic imaging</topic><topic>Heart Ventricles - physiopathology</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Logistics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Normal distribution</topic><topic>Oxidative Stress</topic><topic>Prevalence</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>ROC Curve</topic><topic>Spain - epidemiology</topic><topic>Statins</topic><topic>Stroke Volume</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dominguez-Rodriguez, Alberto, MD, PhD</creatorcontrib><creatorcontrib>Abreu-Gonzalez, Pedro, PhD</creatorcontrib><creatorcontrib>Avanzas, Pablo, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dominguez-Rodriguez, Alberto, MD, PhD</au><au>Abreu-Gonzalez, Pedro, PhD</au><au>Avanzas, Pablo, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Usefulness of Growth Differentiation Factor-15 Levels to Predict Diabetic Cardiomyopathy in Asymptomatic Patients With Type 2 Diabetes Mellitus</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2014-09-15</date><risdate>2014</risdate><volume>114</volume><issue>6</issue><spage>890</spage><epage>894</epage><pages>890-894</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine that increased in patients with established type 2 diabetes mellitus (DM). Diabetic cardiomyopathy (DC), defined as left ventricular diastolic dysfunction (LVDD) in patients with type 2 DM in the absence of arterial hypertension, heart disease, or other heart disease, was assessed by GDF-15 levels in type 2 DM patients with and without DC. A total of 213 DM outpatients had blood samples drawn and on the same day (basal) underwent echocardiography and treadmill exercise testing. Plasma GDF-15 concentrations were measured by an enzyme-linked immunosorbent assay (ELISA) at baseline. DC was diagnosed in the presence of LVDD, defined when early mitral valve flow velocity (E) and early diastolic lengthening velocity (E′) ratio was E/E′ ≥15. The prevalence of DC was 21.13%. GDF-15 levels were higher in patients with DC compared with those without DC (5,273 [8,708.4] vs 2,812.66 [7,662.1] pg/ml, respectively, p <0.001). We assessed predictors of DC using multivariate regression analysis. GDF-15 (odds ratio 9.9; 95% confidence interval [3.9 to 24.5], p <0.001) was the unique independent predictor of DC. The results of receiver operating characteristic curve show that the cut-off point of 3,812 pg/ml of GDF-15 was indicative for DC (AUC = 0.83, sensitivity = 82.2% and specificity = 70.2%, p <0.0001). In conclusion, GDF-15 represents a useful and novel tool to screen DC in patients with type 2 DM.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25073564</pmid><doi>10.1016/j.amjcard.2014.06.020</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2014-09, Vol.114 (6), p.890-894 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1561969806 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE; ProQuest Central UK/Ireland |
| subjects | Biomarkers - blood Body mass index Cardiomyopathy Cardiovascular Cardiovascular disease Confidence intervals Cytokines Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetic Cardiomyopathies - blood Diabetic Cardiomyopathies - epidemiology Diabetic Cardiomyopathies - etiology Echocardiography Electrocardiography Enzyme-Linked Immunosorbent Assay Enzymes Exercise Test Female Fitness equipment Flow velocity Gender Growth Differentiation Factor 15 - blood Heart attacks Heart failure Heart Ventricles - diagnostic imaging Heart Ventricles - physiopathology Humans Hypertension Logistics Male Middle Aged Normal distribution Oxidative Stress Prevalence Prognosis Regression analysis ROC Curve Spain - epidemiology Statins Stroke Volume Variables |
| title | Usefulness of Growth Differentiation Factor-15 Levels to Predict Diabetic Cardiomyopathy in Asymptomatic Patients With Type 2 Diabetes Mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T10%3A39%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Usefulness%20of%20Growth%20Differentiation%20Factor-15%20Levels%20to%20Predict%20Diabetic%20Cardiomyopathy%20in%20Asymptomatic%20Patients%20With%20Type%202%20Diabetes%20Mellitus&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Dominguez-Rodriguez,%20Alberto,%20MD,%20PhD&rft.date=2014-09-15&rft.volume=114&rft.issue=6&rft.spage=890&rft.epage=894&rft.pages=890-894&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/j.amjcard.2014.06.020&rft_dat=%3Cproquest_cross%3E1561969806%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1613816230&rft_id=info:pmid/25073564&rft_els_id=S0002914914013678&rfr_iscdi=true |